Efficacy and safety of rabeprazole in the treatment of reflux esophagitis: a Meta-analysis

doi:10.19803/j.1672-8629.2022.06.14

Abstract

Abstract: Objective To systematically evaluate the efficacy and safety of rabeprazole versus omeprazole in the treatment of reflux esophagitis (RE) and to provide reference for clinical rational drug use. Methods The databases of CNKI, Wanfang Data, CQVIP、PubMed, Cochrane Library, Web of Science and Embase were searched for related articles published from inception to December 3, 2020. Randomized controlled trials (RCT) with rabeprazole versus omeprazole in the treatment of RE were included, and the data needed was retrieved and analyzed using RevMan5.3. Results Fifteen RCTs were included in the study, involving a total of 1 607 patients. Meta-analysis results showed that the total effective rate of rabeprazole in the treatment of RE was higher than that of omeprazole[OR=4.46, 95%CI (3.01~6.59), P<0.001]. Subgroup analysis showed that the total effective rate after 4 weeks and 8 weeks of treatment was higher in the experimental group than in the control group [OR=3.10, 95%CI (1.63~5.90), P<0.001; [OR=5.41, 95%CI (3.29~8.91), P<0.001]. Endoscopy suggested that rabeprazole was more effective than omeprazole, and the difference was statistically significant [OR=0.36, 95%CI (0.22~0.59), P<0.001]. In addition, the incidence of adverse reactions in the rabeprazole group was lower than that of the omeprazole group [OR=0.32,95%CI (0.18,0.56), P<0.001]. Conclusion Rabeprazole is more effective in the treatment of RE than omeprazole, and the incidence of adverse reactions is lower, but omeprazole is cheaper. Clinicians can select appropriate drugs for patients on the basis of safety, effectiveness and cost of drugs.

Key words: rabeprazole, omeprazole, reflux esophagitis, Meta analysis

CLC Number:

LU Song, YANG Li, DONG Xianzhe, ZHANG Lan. Efficacy and safety of rabeprazole in the treatment of reflux esophagitis: a Meta-analysis[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 649-653.

References

[1] BOR S.Reflux esophagitis,functional and non-functional[J]. Best Pract Res Clin Gastroenterol, 2019, 40: 101649.
[2] ROARK R, SYDOR M, CHATILA AT, et al.Management of gastroesophageal reflux disease[J]. Dis Mon, 2020, 66(1): 100849.
[3] SAVARINO E, MARABOTTO E, BODINI G, et al.Epidemiology and natural history of gastroesophageal reflux disease[J]. Minerva Gastroenterol Dietol, 2017, 63(3): 175-183.
[4] ZOU DW, HE J, MA XQ, et al.Epidemiology of symptomdefined gastroesophageal reflux disease and refluxesophagitis: the systematic investigation of gastrointestinal diseases in China(SILC)[J]. Scand J Gastroenterol, 2011, 46(2): 133-141.
[5] LI ML, ZHANG WJ, GUOLL. Efficacy and safety of vonoprazan versus PPIs in treating reflux esophagitis:a Meta-analysis[J]. Chin Gen Pract(中国全科医学), 2021, 24(6): 712-717.
[6] ZHAO WL, CHEN X, CHEN FY.Effects of proton pump inhibitors in the treatment of reflux esophagitis: a mesh Meta-analysis[J]. Chin J Gastroenterol Hepatol(胃肠病学和肝病学杂志), 2017, 26(6): 697-703.
[7] HEIJKOOP B, PARKER N, KIROFF G, et al.Effectiveness and safety of inpatient versus extended venous thromboembolism (VTE) prophylaxis with heparin following major pelvic surgery for malignancy: protocol for a systematic review[J]. Syst Rev, 2019, 8(1): 249.
[8] ZHANG WN.Clinical efficacy of omeprazole and rabeprazole in the treatment of reflux esophagitis[J]. Med Info(医学信息), 2014(21): 145-145.
[9] WANG P.Comparative study of the clinical efficacy of omeprazole and rabeprazole in the treatment of patients with reflux esophagitis[J]. Pract J Cardiac Cereb Pneum Vasc Dis(实用心脑肺血管病杂志), 2018, 26(z1): 48-49.
[10] SU HJ.Comparative analysis of clinical efficacy of rabeprazole and omeprazole in the treatment of reflux esophagitis[J]. Chin J Tradit Med Sci Technol(中国中医药科技), 2014 (z2): 189-189.
[11] TANG CL.Clinical observation of rabeprazole and omeprazole in the treatment of elderly reflux esophagitis[J]. Gems of Health(健康必读), 2019, 1(3): 91.
[12] CHEN H.Clinical effect analysis of rabeprazole and omeprazole in the treatment of senile reflux esophagitis[J]. Guide China Med(中国医药指南), 2018, 16(28): 80.
[13] WANG Z, PENG LL.Efficacy of rabeprazole and omeprazole in the treatment of senile reflux esophagitis[J]. Primary Med Care Forum(基层医学论坛), 2017, 21(7): 825-826.
[14] ZHONG YF.Comparison of rabeprazole and omeprazole in the treatment of reflux esophagitis[J]. Renowned Doctor(名医), 2020(4): 271.
[15] GUANG ZD.Comparison of the efficacy of rabeprazole and omeprazole in the treatment of reflux esophagitis[J]. Pract J Clin Med(实用临床医药杂志), 2013, 17(17): 105-107.
[16] TANG Z.Comparative analysis of clinical effects of rabeprazole and omeprazole in the treatment of reflux esophagitis[J]. Dietary Health(饮食保健), 2018, 5(6): 4.
[17] HUANG JH.Clinical value of rabeprazole and omeprazole in the treatment of elderly reflux esophagitis[J]. Contemp Med(当代医学), 2020, 26(20): 48-50.
[18] LIANG YL.Proton pump inhibitors in the treatment of elderly reflux esophagitis[J]. Chinese Journal of Urban and Rural Enterprise Hygiene(中国城乡企业卫生), 2017, 32(8): 111-112.
[19] GUO HW.Efficacy of rabeprazole and promeprazole in the treatment of senile reflux esophagitis[J]. Contemp Med Forum(当代医药论丛), 2016, 14(1): 121-122.
[20] DENG WJ, MA YC.Clinical efficacy of rabeprazole and omeprazole in the treatment of senile reflux esophagitis[J]. China Health Care & Nutrition(中国保健营养), 2016, 26(26): 104-105.
[21] GAO DQ.Efficacy analysis of rabeprazole in the treatment of 48 cases of elderly esophagitis[J]. J North Pharm(北方药学), 2015(11): 134-134, 135.
[22] SONG H.Clinical efficacy of rabeprazole in the treatment of refractory reflux esophagitis and its effect on recurrence rate[J].Guide China Med(中国医药指南), 2020, 18(27): 105-106.
[23] VAKIL N, VAN ZANTEN S V, KAHRILAS P, et al. The Montreal definition and classification of gastro esophageal reflux disease: a global evidence-based consensus[J]. Am J Gastroenterol, 2006, 101(8): 1900-1920.
[24] LIU WZ.Interpretation of the 2013 american college of gastroen-terology gastroesophageal reflux disease diagnosis and management guidelines[J]. Chinese Journal of Gastroenterology(胃肠病学), 2013, 18(4): 193-199.
[25] LABENZ J, ARMSTRONG D, LAURITSEN K, et al.A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study[J]. Aliment Pharmacol Ther, 2005, 21(6): 739-746.
[26] PACE F, ANNESE V, PRADA A, et al.Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole[J]. Dig Liver Dis, 2005, 37(10): 741-750.
[27] PARK JH, PARK H, LEE DH, et al.A randomized, double blinded, clinical trial to assess the efficacy and cost effectiveness of omeprazole compared to rabeprazole in the maintenance therapy of patients with gastroesophageal reflux disease[J]. J Neurogastroenterol Motil, 2013, 19(2): 219-226.
[28] ZHANG Q.Efficacy of rabeprazole combined with compound glutamine in treatment of helicobacter pylori negative gastric ulcer[J]. Chin J pharmaovi(中国药物警戒), 2017, 14(1): 19-21,31.
[29] SAHARA S, SUGIMOTO M, UOTANI T, et al.Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole[J]. Alimentary Pharmacology & Therapeutics, 2013, 38(9): 1129-1137.
[30] LI XQ, ANDERSSON TB, AHLSTRÖM M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities[J]. Drug Metab Dispos, 2004, 32(8): 821-827.
[31] ISHIZAKI T, HORAI Y.Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole[J].Aliment Pharmacol Ther, 1999,13(6): 27-36.